Anyone know of other companies doing this?
InNexus to Develop SuperAntibody for Treatment of Coronary Heart Disease (Plaque)
T15 demonstrates reduction of plaque by 20-25% in animal models
TSX-V: IXS
VANCOUVER, Oct. 13 /CNW/ - InNexus Biotechnology, Inc. is pleased to
announce that it has received approval from the TSX Venture Exchange for the
acquisition of monoclonal antibodies and related intellectual property from
ImmPheron Inc. of Lexington, Kentucky. InNexus intends to initiate the product
development of the S(T15) SuperAntibody as its lead SuperAntibody product as
it believes that S(T15) represents, potentially, the most efficacious product
currently in the marketplace or in development for reducing plaque in the
treatment of Coronary Heart Disease ("CHD").
Dr. A. Charles Morgan, President, said, "I'm extremely proud of the
progress we have made with our S(T15) SuperAntibody product for the treatment
of CHD. We are on track for clinical development and believe this
SuperAntibody represents the best opportunity for treatment of plaque."
A major factor of CHD is the build-up of plaque. When the coronary
arteries become narrowed or clogged by fat and cholesterol deposits, the heart
is starved of needed blood supply. Recent studies show the number of total
prevalent cases of CHD will be approximately 217 million in 2012. The market
for CHD products is expected to reach $15 billion in 2007, growing to $23
billion in 2012. Current treatment is based on the use of statins, which lower
cholesterol levels and represent over $10 billion in annual sales. Statins
have demonstrated only a 1% reduction of plaque in arteries. Recently
Atherogenics Inc. (NASDAQ: AGIX) announced a novel anti-inflammatory agent
that they claim demonstrated a 3.8% reduction in plaque in clinical studies.
The treatment approach and distinctive mechanism of action of the S(T15)
SuperAntibody has been demonstrated in animal models to reduce plaque by 20-
25%. There is no guarantee that such results will translate into clinical
efficacy, though the same animal model used for evaluation has been used for
evaluation of other anti-plaque drugs.
InNexus and ImmPheron have filed for intellectual property protection for
the use of this SuperAntibody for the treatment of CHD. InNexus believes its
intellectual property positioning of SuperAntibody Technology and specific
claims for product indications will enable it to fully protect this treatment
approach for CHD and enable it ultimately to co-develop or out-license the
product to partners.
About InNexus
InNexus is developing the next generation of therapeutic, monoclonal
antibodies using its SuperAntibody Technology Platform. InNexus intends to
apply this technology to improve the potency of existing antibody products
while opening new markets and disease applications with other forms of
SuperAntibodies. InNexus will develop the technology through partnerships with
biotechnology and pharmaceutical companies while pursuing development of its
own products for unmet medical needs. To learn more about InNexus please visit
the Company's website: www.innexusbiotech.com |
